Human papillomavirus (HPV) is a well-known sexually transmitted disorder globally. Human papillomavirus (HPV) is the 3rd most common
cancer that causes cervical
carcinoma, and globally it accounts for 275,000 deaths every year. The load of HPV-associated abrasions can be lessened through vaccination. At present, three forms of prophylactic
vaccines,
Cervarix, Gadrasil, and
Gardasil 9, are commercially accessible but all these prophylactic
vaccines have not the ability to manage and control developed abrasions or
infections. Therefore, a considerable amount of the population is not secured from HPV infectivity. Consequently, the development of therapeutic
HPV vaccines is a crucial requirement of this era, for the treatment of persisting
infections, and to stop the progression of HPV-associated
cancers. Therapeutic
vaccines are a developing trial approach. Because of the constitutive expression of E6 and E7 early genes in cancerous and pre-cancerous tissues, and their involvement in disturbance of the cell cycle, these are best targets for this therapeutic
vaccine treatment. For the synthesis and development of therapeutic
vaccines, various approaches have been examined comprising cell-based
vaccines, peptide/
protein-based
vaccines, nucleic acid-based vaccines, and live-vector
vaccines all proceeding towards clinical trials. This review emphasizes the development, progress, current status, and future perspective of several
vaccines for the cure of HPV-related abrasions and
cancers. This review also provides an insight to assess the effectiveness, safety, efficacy, and immunogenicity of therapeutic
vaccines in the cure of patients infected with HPV-associated
cervical cancer.